NCT05385575View on ClinicalTrials.gov

A Study to Evaluate Effects of KN056 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

December 22, 2023

Study Completion Date

February 29, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

KN056 (0.1mg)

The participants will receive assigned single dose of KN056 on Day 1

DRUG

KN056 (0.3mg)

The participants will receive assigned single dose of KN056 on Day 1

DRUG

KN056 (1.0mg)

The participants will receive assigned single dose of KN056 or placebo on Day 1

DRUG

KN056 (3.0mg)

The participants will receive assigned single dose of KN056 or placebo on Day 1

DRUG

KN056 (6.0mg)

The participants will receive assigned single dose of KN056 or placebo on Day 1

DRUG

KN056 (12.0mg)

The participants will receive assigned single dose of KN056 or placebo on Day 1

DRUG

KN056 (18.0mg)

The participants will receive assigned single dose of KN056 or placebo on Day 1

Trial Locations (1)

8011

Alexandra Cole, Christchurch

All Listed Sponsors

collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Suzhou Alphamab Co., Ltd.

INDUSTRY